Actavis' Viberzi, Valeant's Xifaxan OK'd in IBS-D in US

 
• By Donna Young
  
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

More from Therapeutic Category